Tissue Diagnostics Market by Product(Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology(ISH, IHC, Special Staining), Disease(Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories) - Global Forecast to 2027
[246 Pages Report] The global Tissue Diagnostics market is growing at a CAGR of 6.6% during and it is expected to reach USD 7.3 billion by 2027 from USD 5.3 billion in 2022, during the forecast period. The expansion of this market is majorly due to rising prevalence of neoplastic cases as well as high demand of oncology screening, However, Lack of skilled professionals is one of the challenge for which may inhibit the growth of this market.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID -19 Impact
Globally, the COVID-19 outbreak has impacted every aspect of the pharmaceutical, diagnostics, and medical industry, including the tissue diagnostics market
COVID-19 positively impacted the market due to a growing demand for high-throughput and sequencing-based diagnostic tests. For instance, Brooks Automation’s Life Science segment reported USD 199.6 million in revenue in 2021, compared to USD 129.8 million in 2020, with an increase of USD 69.8 million (54%). Likewise, in 2021, the revenue of Roche Diagnostics increased by 28% due to COVID-19.
The number of cancer screening and diagnostic procedures declined precipitously, with countries worldwide being affected by the pandemic. An initial analysis of the US market shows that newly diagnosed metastatic non-small-cell lung cancer patient volumes have declined just over 30% from February 2020 to March 2020—this represents a major decline in just one month. This also impacted KRAS, BRAF, and EGFR testing rates, which are the key biomarkers supporting the appropriate selection of precision medicine therapies that benefit certain patients. Nearly 4,000 EGFR tests were performed in February when most of the country initiated strict “stay-at-home” orders, representing a 13% drop from the previous month.
The following are some of the government initiatives to delay screening or diagnostic tests for cancer:
In March 2020, the Welsh Government and the Scottish Government suspended the screening programs for breast, cervical, and bowel cancer.
In the US, the CMS classified screening as a low-priority service and suggested healthcare organizations consider postponing screenings.
The interim Chief Medical Officer of Scotland reported that the urgent referrals of patients with cancer by primary-care physicians had been reduced by over 70% by mid-April compared with the weekly average over the past three years. Similar reductions have been reported in England. Assuming urgent cancer referrals have a conversion rate of 7%, Cancer Research UK has estimated that this reduction in referrals could mean around 2,000 fewer cancers are being diagnosed per week.
Histopathology diagnostic services such as autopsy, screening services, teaching, training and quality assurance all these services have been impacted by COVID-19. The pre-analytic phase majorly involves the handling of biological materials, such as fresh tissue for research or frozen sections and formalin-fixed tissue and organs of varying sizes. These tissues are looked upon as a possible transmission route for SARS-CoV-2. As a result, fresh tissue handling was distressed by the guidelines produced by RCPath, ABPath (Association of breast surgery and pathology), and BAGP (The British Association of Gynecological); for instance, In March 2020, RCPath advised on histopathology, frozen sections, and cytology fine needle objective during infectious disease.
Research associations and other medical bodies are making various attempts to conduct clinical trials to develop suitable anti-COVID drugs or testing devices, which is anticipated to fuel the growth of the tissue diagnostics market.
Additionally, the closure of manufacturing facilities disrupted supply chains and reduced recruitments. For instance, in the UK, universities, sponsors, charities, NHS institutions, and NIHR Clinical Research Network decided to stop all non-COVID-related research in March 2020 and to pause the setup of new trials too. However, in the 2022 recovery phase, restoring clinical trials will be a challenge because of restricted access at trial sites. Hence, further delays in clinical trials might impact the growth of the overall tissue diagnostics market in 2022.
Soon as the FDA implemented regulatory cautions regarding how digital pathology systems could be used during the pandemic, many pathologists started working flexibly in remote locations to minimize the COVID-19 exposure risks and provide timely diagnoses. As a result, the tissue diagnostics market rose to a high extent.
In conclusion, the emergence of new variants of COVID will increase the demand for new clinical trials to identify and evaluate the effectiveness of drugs against COVID-19 during the forecast period.
Global Tisue Diagnostic Market Dynamics
DRIVER: Rising prevalence of cancer
Cancer is a complex disease that develops through the multi-stage carcinogenesis process involving multiple pathways. As a result, there are various hurdles associated with a cancer diagnosis, prognosis, and therapy. According to the WHO, one-fifth of all cancers worldwide are caused by chronic infectious agents, for instance, hepatitis B virus, HIV, HPV, and Helicobacter pylori. According to GLOBACON, cancer prevailed among 37.4 million (including 18.1 nonmelanoma skin cancer) population and accounted for 19.9 (including 9.9 nonmelanoma skin cancer) million deaths in 2020. The increase in the incidence of cancer can be attributed to the growing geriatric as well as the total population.
According to estimates from the International Agency for Research on Cancer (IARC), globally, new cancer cases are expected to grow to 27.5 million, and 16.3 million cancer deaths are expected to occur due to the growing number of total and aged population by 2040.
The incidence of cancer is the highest in developed regions; however, cancer mortality is relatively higher in underdeveloped regions due to factors such as a lack of access to treatment facilities and the late detection of cancer in several patients. According to the WHO, for many types of cancers, the incidence rate in countries with high or very high HDI1 is generally 2 to 3 times that in countries with low or medium HDI. Also, approximately 70% of deaths due to cancer were reported in low-income and middle-income countries in 2020 (Source: ACS).
In addition, during the frozen section procedure, the surgeon removes a portion of the tissue. This biopsy is given to a pathologist, who freezes the tissue in a cryostat machine, cuts it with a microtome, and stains it with various dyes so that it can be examined under the microscope. Similarly, histopathology is the microscopic study of the diseased tissue and is a vital part of anatomical pathology since the accurate diagnosis of cancer and other diseases usually requires histopathological examination of the samples. Microtomes, tissue processors are a key tool used in tissue diagnostics.
Due to the increasing prevalence of cancer, the demand for oncology diagnostics has increased significantly. This has compelled government organizations, healthcare providers, and institutions to provide facilities for effective disease diagnosis and treatment. This is driving the demand for tissue diagnostics. In 2021, Roche launched two digital pathology image analyzers, uPath HER2 (4B5) and uPath HER2 Dual ISH, algorithms for precision patient diagnosis in breast cancer.
OPPORTUNITY: Growing focus on personalized medicine
The demand for excised human tissue is increasing due to the growing awareness regarding personalized medicines, which depend on excised human tissue to create an innovative test for application in patient care. The demand for personalized medicine in the treatment of many disorders, mainly cancer, is increasing with the advancements in diagnostic tools. These technologies assist physicians in detecting and quantifying multiple biomarkers and dividing patients into subgroups on various disease and treatment grounds. Several advanced diagnostics are already in use for cancer treatment. For instance, the test called Oncotype DX, one of the advanced diagnostics for personalized medicine examines 21 genes and identifies the women with breast cancer who can be treated without chemotherapy. Personalized medicines accounted for over a third of new drug approvals in 2021 and 25% or more of all FDA approvals for each of the last seven years. Major pharma companies such as AstraZeneca confirm that approximately 90% of their clinical development revenue is currently obtained by precision therapeutics. Some of the leading pharma companies for precision medicine include Novartis, Roche, Genentech, Astra Zeneca, Pfizer, BMS, Merck, and Amgen. Moreover, it has also been predicted that the personalized medicine sector is expected to reach around 98 billion USD by 2026. Likewise, the number of personalized medicines in the US market has grown from 132 in 2016 to 286 in 2020. Similarly, in vitro diagnostic reagents, test products, instrumentation, and other related products, which are widely used by both clinical and research laboratories, are an integral part of the development of personalized medicine. As a result, the in vitro diagnostic (IVD) market is expected to grow from USD 87.93 billion in 2018 to USD 68.12 billion by 2023, at a CAGR of 5.2% (Source: MarketsandMarkets—IVD Market Report), which is supposed to provide opportunities for the growth of the tissue diagnostics market (as tissue diagnostics is a part of in vitro diagnostics).
CHALLENGE: Lack of skilled professionals
Histology laboratories play a vital role in healthcare, as histology is important for the accuracy, safety, and timeliness of disease diagnosis. Histology is essential in gaining a better understanding of disease mechanisms and the effects of drugs on tissues. The demand for histology services has increased significantly for clinical applications due to the increasing prevalence of cancer. Histopathology technologies account for more than 80% of the tests performed on cancer patients. However, there is a lack of trained staff in these laboratories. For instance, as per the inside lab 2020, in the UK, only 3% of diagnostic laboratories had sufficient staff to deliver their diagnostic and routine tasks such as reporting workload. Moreover, the ratio of pathologists among the physicians working in Germany is the lowest in Europe and lower than in the US and Canada. In Germany 1:200, USA 1:70, Canada 1:49 (Source PubMed 2020). Many histologists have reached retirement age, and fewer histologists are being trained. As a result, histology laboratories are under pressure to process an increasing number of specimens with limited staff. This is expected to hamper the growth of the tissue diagnostics market.
North America dominates the global tissue diagnostics market
Based on the region, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to dominate the market. Growth in the North American market is mainly driven by the easy accessibility to advanced technologies, the increased prevalence of chronic lifestyle & genetic diseases and the rapidly growing aging population are other important factors driving the market in North America.
To know about the assumptions considered for the study, download the pdf brochure
Some of the major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific, Inc (US), Abbott (US), Agilent Technologies Inc. (US), Merck KGAA (Germany), SAKURA FINETEK JAPAN CO., LTD (Japan), Abcam Plc. (UK), Becton, Dickinson and Company (BD) (US), Bio SB (US), Biogenix (US), Cell Signaling Technology, Inc (US), Histo-Line Laboratories (Italy), SLEE Medical GMBH (Germany), and Hologic Inc. (US)
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size Available for Years |
2017–2027 |
|
Base Year Considered |
2021 |
|
Forecast Period |
2022–2027 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Product, technology, Disease, End user and Region |
|
Geographies Covered |
North America (US, Canada), Europe (Germany, France, UK, Spain, Italy and RoE), APAC (China, India, Japan, and the RoAPAC), and Rest of the World (Latin America- and Middle East & Africa) |
|
Companies Covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific, Inc (US), Abbott (US), Agilent Technologies Inc. (US), Merck KGAA (Germany), SAKURA FINETEK JAPAN CO., LTD (Japan), Abcam Plc. (UK), Becton, Dickinson and Company (BD) (US), Bio SB (US), Biogenix (US), Cell Signaling Technology, Inc (US), Histo-Line Laboratories (Italy), SLEE Medical GMBH (Germany), Hologic Inc. (US). Jinhua YIDI Medical Appliance Co. Ltd (China), MEDITE MEDICAL GMBH (Germany), Cellpath Ltd (UK), Amos scientific Pty Ltd (Australia), Dipath S.P.A (Italy), KFBIO KONFOONG BIOINFORMATION TECH CO., LTD (China), Diagnostic BioSystems Inc. (US), 3DHISTECH LTD (Hungary), RWD LIFE SCIENCE CO., LTD. (China), Dakewe Biotech Co., Ltd. (China). |
This research report categorizes the tissue diagnostics market into the following segments and subsegments:
Regional Split
- North America
- Europe
- Asia pacific
- Rest of the World
Product Split
- Consumables
- Antibodies
- Kits
- Reagents
- Probes
- Instruments
- Slide-staining Systems
- Scanners
- Tissue-processing Systems
- Other Instruments
Technology Split
- Immunohistochemistry
- In Situ Hybridization
- Digital Pathology and Workflow
- Management
- Special Staining
Disease Split
- Breast Cancer
- Gastric Cancer
- Lymphoma
- Prostate Cancer
- Non-small Cell Lung Cancer
- Other Diseases
End-user Split
- Hospitals
- Pharmaceutical Companies
- Research Laboratories
- Contract Research Organizations
- Other End Users
Recent Developments:
- In 2020, Diapath S.P.A. (Italy) launched Cristallo, Galileo S2 Pro microtome.
- In 2021, F. Hoffmann-La Roche Ltd. (Switzerland) announced the launch of the DISCOVERY Green HRP kit for cancer research.
- In 2022, Leica Biosystems (Nussloch, Germany) has launched a compact dual-retort tissue processor, the HistoCore PEGASUS Plus.
Frequently Asked Questions (FAQ):
What is the projected market value of the global tissue diagnostics market?
The global market of tissue diagnostics market is projected to reach USD 7.3 billion by 2027.
What is the estimated growth rate (CAGR) of the global tissue diagnostics market for the next five years?
The global tissue diagnostics market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% from 2022 to 2027.
Who are the major players offering tissue diagnostics in the market?
F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific, Inc (US), Abbott (US), Agilent Technologies Inc. (US), Merck KGAA (Germany), SAKURA FINETEK JAPAN CO., LTD (Japan), Abcam Plc. (UK), Becton, Dickinson and Company (BD) (US), Bio SB (US), Biogenix (US), Cell Signaling Technology, Inc (US), Histo-Line Laboratories (Italy), SLEE Medical GMBH (Germany), and Hologic Inc. (US) .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 29)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 GEOGRAPHIC SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 34)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: DANAHER CORPORATION
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1 GROWTH FORECAST
FIGURE 7 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
FIGURE 8 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
3 EXECUTIVE SUMMARY (Page No. - 47)
FIGURE 10 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 12 MARKET, BY DISEASE, 2022 VS. 2027 (USD MILLION)
FIGURE 13 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 14 GEOGRAPHIC SNAPSHOT OF GLOBAL TISSUE DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS (Page No. - 51)
4.1 TISSUE DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
4.2 MARKET, BY PRODUCT
FIGURE 16 EQUIPMENT IN TISSUE DIAGNOSTICS SEGMENT TO REGISTER HIGHEST CAGR DURING 2022-2027.
4.3 ASIA PACIFIC: MARKET, BY DISEASE & COUNTRY
FIGURE 17 GASTRIC CANCER SEGMENT TO DOMINATE ASIA PACIFIC MARKET IN 2022
4.4 GEOGRAPHIC SNAPSHOT OF MARKET
FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 54)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of cancer
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
5.2.1.2 Growing demand for digital pathology
5.2.1.3 Increasing healthcare expenditure
FIGURE 20 CURRENT HEALTH EXPENDITURE PER CAPITA
FIGURE 21 CURRENT HEALTH EXPENDITURE (% OF GDP)
5.2.1.4 Developing infrastructure for cancer diagnosis
5.2.1.5 Increasing availability of reimbursements
5.2.1.6 Growing private diagnostics centers globally
5.2.1.7 Rising geriatric population with subsequent growth in chronic and infectious diseases
FIGURE 22 ESTIMATED INCREASE IN CANCER INCIDENCE (IN MILLION)
FIGURE 23 ESTIMATED DEATHS OF CANCER (IN MILLION)
5.2.2 RESTRAINTS
5.2.2.1 High degree of consolidation
5.2.3 OPPORTUNITIES
5.2.3.1 Significant opportunities in BRICS countries
FIGURE 24 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012–2019
5.2.3.2 Growing demand for personalized medicines
FIGURE 25 GROWTH OF PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2021
5.2.3.3 Increasing number of clinical trials pertaining to cancer drugs
FIGURE 26 NUMBER OF ARTICLES RELATED TO TISSUE DIAGNOSTICS PUBLISHED ON PUBMED (2011–2021)
5.2.3.4 Emerging economies to offer significant opportunities to companies
5.2.4 CHALLENGES
5.2.4.1 Lack of skilled professionals
TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
5.2.4.2 Availability of refurbished products
5.2.4.3 Product failures and recalls
5.2.4.4 Stringent regulatory requirements
5.2.4.5 Lack of infrastructure and low awareness in middle and low income countries
5.2.5 TRENDS
5.2.5.1 Increasing number of reagent rental agreements
5.2.5.2 Increasing usage of AI in histopathology
5.3 COVID-19 IMPACT ON TISSUE DIAGNOSTICS MARKET
5.4 RANGES/SCENARIOS
5.4.1 TISSUE DIAGNOSTICS MARKET
FIGURE 27 PESSIMISTIC SCENARIO
FIGURE 28 OPTIMISTIC SCENARIO
FIGURE 29 REALISTIC SCENARIO
5.5 VALUE CHAIN ANALYSIS
FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 31 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.7 TECHNOLOGY ANALYSIS
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 INTENSITY OF COMPETITIVE RIVALRY
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 THREAT OF SUBSTITUTES
5.9 KEY STAKEHOLDERS & BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS
TABLE 5 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS (%)
5.9.2 BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR TOP 3 END USERS
TABLE 6 KEY BUYING CRITERIA FOR TOP 3 END USERS
5.10 REGULATORY LANDSCAPE
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING TISSUE DIAGNOSTICS MARKET
5.11 PATENT ANALYSIS
5.12 KEY CONFERENCES & EVENTS IN 2022-2023
TABLE 8 LIST OF CONFERENCES & EVENTS
5.13 PRICING ANALYSIS
TABLE 9 PRICE RANGE FOR TISSUE DIAGNOSTICS
5.14 TRADE ANALYSIS
TABLE 10 IMPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 11 EXPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION)
5.15 ECOSYSTEM ANALYSIS
TABLE 12 ROLE IN ECOSYSTEM
FIGURE 34 KEY PLAYERS OPERATING IN TISSUE DIAGNOSTICS MARKET
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 84)
6.1 INTRODUCTION
TABLE 13 MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
6.2 CONSUMABLES
TABLE 14 MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
TABLE 15 MARKET FOR CONSUMABLES, BY REGION, 2019–2027 (USD MILLION)
6.2.1 ANTIBODIES
TABLE 16 MARKET FOR ANTIBODIES, BY REGION, 2019–2027 (USD MILLION)
6.2.2 KITS
TABLE 17 MARKET FOR KITS, BY REGION, 2019–2027 (USD MILLION)
6.2.3 REAGENTS
TABLE 18 MARKET FOR REAGENTS, BY REGION, 2019–2027 (USD MILLION)
6.2.4 PROBES
TABLE 19 MARKET FOR PROBES, BY REGION, 2019–2027 (USD MILLION)
6.3 INSTRUMENTS
TABLE 20 MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
TABLE 21 MARKET FOR INSTRUMENTS, BY REGION, 2019–2027 (USD MILLION)
6.3.1 SLIDE-STAINING SYSTEMS
TABLE 22 MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2019–2027 (USD MILLION)
6.3.2 SCANNERS
TABLE 23 MARKET FOR SCANNERS, BY REGION, 2019–2027 (USD MILLION)
6.3.3 TISSUE-PROCESSING SYSTEMS
TABLE 24 MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 2019–2027 (USD MILLION)
6.3.4 OTHER INSTRUMENTS
TABLE 25 MARKET FOR OTHER INSTRUMENTS, BY REGION, 2019–2027 (USD MILLION)
7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 94)
7.1 INTRODUCTION
TABLE 26 MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
7.2 IMMUNOHISTOCHEMISTRY (IHC)
TABLE 27 MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2019–2027 (USD MILLION)
7.3 IN SITU HYBRIDIZATION (ISH)
TABLE 28 MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019–2027 (USD MILLION)
7.4 DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT
TABLE 29 MARKET FOR DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT, BY REGION, 2019–2027 (USD MILLION)
7.5 SPECIAL STAINING
TABLE 30 MARKET FOR SPECIAL STAINING, BY REGION, 2019–2027 (USD MILLION)
8 TISSUE DIAGNOSTICS MARKET, BY DISEASE (Page No. - 100)
8.1 INTRODUCTION
TABLE 31 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
FIGURE 35 ARTICLES PUBLISHED ON CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 32 MARKET, BY DISEASE, 2019–2027 (USD MILLION)
8.2 BREAST CANCER
TABLE 33 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
FIGURE 36 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 34 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2019–2027 (USD MILLION)
8.3 GASTRIC CANCER
TABLE 35 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
FIGURE 37 ARTICLES PUBLISHED ON GASTRIC CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 36 MARKET FOR GASTRIC CANCER, BY REGION, 2019–2027 (USD MILLION)
8.4 LYMPHOMA
TABLE 37 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 38 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025
FIGURE 38 ARTICLES PUBLISHED ON LYMPHOMA TISSUE DIAGNOSTICS, 2011–2021
TABLE 39 MARKET FOR LYMPHOMA, BY REGION, 2019–2027 (USD MILLION)
8.5 PROSTATE CANCER
TABLE 40 PROSTATE CANCER INCIDENCE, BY REGION, 2018 VS. 2025
FIGURE 39 ARTICLES PUBLISHED ON PROSTATE CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 41 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2019–2027 (USD MILLION)
8.6 NON-SMALL CELL LUNG CANCER
TABLE 42 NON-SMALL CELL LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
FIGURE 40 ARTICLES PUBLISHED ON NON-SMALL CELL LUNG CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 43 MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2019–2027 (USD MILLION)
8.7 OTHER DISEASES
TABLE 44 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2019–2027 (USD MILLION)
9 TISSUE DIAGNOSTICS MARKET, BY END USER (Page No. - 112)
9.1 INTRODUCTION
TABLE 45 MARKET, BY END USER, 2019–2027 (USD MILLION)
9.2 HOSPITALS
TABLE 46 MARKET FOR HOSPITALS, BY REGION, 2019–2027 (USD MILLION)
9.3 RESEARCH LABORATORIES
TABLE 47 MARKET FOR RESEARCH LABORATORIES, BY REGION, 2019–2027 (USD MILLION)
9.4 PHARMACEUTICAL COMPANIES
TABLE 48 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2019–2027 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
TABLE 49 ONCOLOGY CONTRACT RESEARCH ORGANIZATIONS (CROS).
TABLE 50 MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2027 (USD MILLION)
9.6 OTHER END USERS
TABLE 51 MARKET FOR OTHER END USERS, BY REGION, 2019–2027 (USD MILLION)
10 TISSUE DIAGNOSTICS MARKET, BY REGION (Page No. - 118)
10.1 INTRODUCTION
TABLE 52 TISSUE DIAGNOSTICS MARKET, BY REGION, 2019–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 41 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 42 TISSUE DIAGNOSTICS MARKET IN NORTH AMERICA: SNAPSHOT
TABLE 53 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2027 (USD MILLION)
TABLE 54 NORTH AMERICA: MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
TABLE 57 NORTH AMERICA: MARKET, BY DISEASE, 2019–2027 (USD MILLION)
TABLE 58 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 59 NORTH AMERICA: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.2.1 US
10.2.1.1 US to dominate country-level market for tissue diagnostics
TABLE 60 US CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 61 US: KEY MACROINDICATORS
TABLE 62 LIST OF US FDA-APPROVED PRODUCTS RELATED TO TISSUE DIAGNOSTICS
TABLE 63 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 64 US: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 65 US: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 High prevalence of cancer to support market growth
TABLE 66 CANADA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 67 CANADA: KEY MACROINDICATORS
TABLE 68 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 69 CANADA: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 70 CANADA: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3 EUROPE
FIGURE 43 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
TABLE 71 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (USD MILLION)
TABLE 72 EUROPE: MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 73 EUROPE: MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
TABLE 74 EUROPE: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
TABLE 75 EUROPE: MARKET, BY DISEASE, 2019–2027 (USD MILLION)
TABLE 76 EUROPE: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 77 EUROPE: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth
TABLE 78 GERMANY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 79 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 80 GERMANY: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 81 GERMANY: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.2 UK
10.3.2.1 Government initiatives to drive market growth
TABLE 82 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 83 UK: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 84 UK: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government funding for cancer diagnosis & prevention to support market growth
TABLE 85 FRANCE CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 86 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 87 FRANCE: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 88 FRANCE: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 High incidence of cancer and geriatric population to support market growth
TABLE 89 ITALY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 90 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 91 ITALY: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 92 ITALY: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 High incidence of chronic diseases to drive market growth
TABLE 93 SPAIN CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 94 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 95 SPAIN: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 96 SPAIN: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 97 LUNG CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040
TABLE 98 LIVER CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040
TABLE 99 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 100 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 101 REST OF EUROPE: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 44 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 45 TISSUE DIAGNOSTICS MARKET IN ASIA PACIFIC: SNAPSHOT
TABLE 102 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2027 (USD MILLION)
TABLE 103 ASIA PACIFIC: MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
TABLE 105 ASIA PACIFIC: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
TABLE 106 ASIA PACIFIC: MARKET, BY DISEASE, 2019–2027 (USD MILLION)
TABLE 107 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 108 ASIA PACIFIC: MARKET, BY END USER, 2019–2027 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Increasing healthcare expenditure and funding to drive market growth
TABLE 109 CHINA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 110 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 111 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 112 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Advanced healthcare infrastructure to support market growth
TABLE 113 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 114 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 115 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 116 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Expanding healthcare sector to drive market growth
TABLE 117 INDIA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 118 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 119 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 120 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 121 INCIDENCE OF CANCER IN REST OF ASIA PACIFIC
TABLE 122 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 123 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 124 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 125 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY REGION, 2019–2027 (USD MILLION)
TABLE 126 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 127 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
TABLE 128 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
TABLE 129 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
TABLE 130 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 131 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.5.1 LATIN AMERICA
10.5.1.1 Increasing number of cancer screening programs to support market growth
TABLE 132 KEY LATIN AMERICAN COUNTRIES LUNG CANCER INCIDENCE, 2018 VS. 2025
TABLE 133 KEY LATIN AMERICAN COUNTRIES LIVER CANCER INCIDENCE, 2018 VS. 2025
TABLE 134 KEY LATIN AMERICAN COUNTRIES BREAST CANCER INCIDENCE, 2018 VS. 2025
TABLE 135 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 136 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 137 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Increasing incidence of cancer to support market growth
TABLE 138 AFRICA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 139 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 140 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 141 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 168)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 142 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
11.3 REVENUE SHARE ANALYSIS
FIGURE 46 REVENUE ANALYSIS OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
11.4 MARKET SHARE ANALYSIS
TABLE 143 TISSUE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 47 COMPANY EVALUATION QUADRANT: TISSUE DIAGNOSTICS MARKET
11.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 48 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: TISSUE DIAGNOSTICS MARKET
11.7 COMPANY FOOTPRINT ANALYSIS
11.7.1 COMPANY FOOTPRINT
11.7.2 COMPANY REGIONAL FOOTPRINT
11.7.3 COMPANY PRODUCT FOOTPRINT
11.8 COMPETITIVE BENCHMARKING
TABLE 144 TISSUE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES/APPROVALS
TABLE 145 KEY PRODUCT LAUNCHES
11.9.2 DEALS
TABLE 146 KEY DEALS
11.9.3 OTHER DEVELOPMENTS
TABLE 147 KEY OTHER DEVELOPMENTS
12 COMPANY PROFILES (Page No. - 181)
(Business Overview, Products Offered, Recent Developments, and MnM View)*
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE LTD
TABLE 148 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 49 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
12.1.2 DANAHER CORPORATION
TABLE 149 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 50 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 150 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
12.1.4 ABBOTT
TABLE 151 ABBOTT: BUSINESS OVERVIEW
FIGURE 52 ABBOTT.: COMPANY SNAPSHOT (2021)
12.1.5 AGILENT TECHNOLOGIES INC.
TABLE 152 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
FIGURE 53 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2021)
12.1.6 MERCK KGAA
TABLE 153 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 54 MERCK KGAA COMPANY SNAPSHOT (2021)
12.1.7 SAKURA FINETEK JAPAN CO., LTD.
TABLE 154 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
12.1.8 ABCAM PLC.
TABLE 155 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 55 ABCAM PLC. COMPANY SNAPSHOT (2021)
12.1.9 BECTON, DICKINSON AND COMPANY (BD)
TABLE 156 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 56 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
12.1.10 BIO SB
TABLE 157 BIO SB: BUSINESS OVERVIEW
12.1.11 BIOGENEX
TABLE 158 BIOGENEX.: BUSINESS OVERVIEW
12.1.12 CELL SIGNALING TECHNOLOGY, INC.
TABLE 159 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
12.1.13 HISTO-LINE LABORATORIES
TABLE 160 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW
12.1.14 SLEE MEDICAL GMBH
TABLE 161 SLEE MEDICAL GMBH.: BUSINESS OVERVIEW
12.1.15 AMOS SCIENTIFIC PTY LTD
TABLE 162 AMOS SCIENTIFIC PTY LTD: BUSINESS OVERVIEW
12.1.16 JINHUA YIDI MEDICAL APPLIANCE CO. LTD
TABLE 163 JINHUA YIDI MEDICAL APPLIANCE CO.LTD: BUSINESS OVERVIEW
12.1.17 MEDITE MEDICAL GMBH
TABLE 164 MEDITE MEDICAL GMBH: BUSINESS OVERVIEW
12.1.18 CELLPATH LTD
TABLE 165 CELLPATH LTD: BUSINESS OVERVIEW
12.1.19 HOLOGIC, INC
TABLE 166 HOLOGIC, INC: BUSINESS OVERVIEW
FIGURE 57 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
12.1.20 DIAPATH S.P.A.
TABLE 167 DIAPATH S.P.A.: BUSINESS OVERVIEW
12.1.21 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD
TABLE 168 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD: BUSINESS OVERVIEW
12.1.22 DIAGNOSTIC BIOSYSTEMS INC.
TABLE 169 DIAGNOSTIC BIOSYSTEMS INC.: BUSINESS OVERVIEW
12.1.23 3DHISTECH LTD.
TABLE 170 3DHISTECH LTD: BUSINESS OVERVIEW
12.1.24 RWD LIFE SCIENCE CO., LTD.
TABLE 171 RWD LIFE SCIENCE CO., LTD.: BUSINESS OVERVIEW
12.1.25 DAKEWEI BIOTECHNOLOGY CO., LTD.
TABLE 172 DAKEWEI BIOTECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 238)
13.1 INDUSTRY INSIGHTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
The study involved four major activities in estimating the current size of the tissue diagnostics market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (heads of private labs, Diagnostics and hospitals, Scientists, Researchers) and supply sides (tissue diagnostics manufacturers and distributors).
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the tissue diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the tissue diagnostics industry.
Report Objectives
- To define, describe, and forecast the tissue diagnostics market by product, technology, disease, end user, and region
- To forecast the size of the market with respect to four main regional segments, namely, North America, Europe, the Asia Pacific, and the Rest of the world
- To provide detailed information regarding the key factors influencing the market growth (drivers, restraints, opportunities, challenges and trends)
- To strategically analyze micromarkets with respect to growth trends, prospects, and contributions to the overall market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile the key players and comprehensively analyze their market shares and core competencies in terms of market developments and growth strategies
- To track and analyze competitive developments such as collaborations, expansions, partnerships, acquisitions, and product approvals & launches in the tissue diagnostics market
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
- Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
- Geographic Analysis: Further breakdown of the European tissue diagnostics market into specific countries.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
Growth opportunities and latent adjacency in Tissue Diagnostics Market